CI · available-data snapshot
The Cigna Group (CI): Available-Data Snapshot
TickerWorth does not publish a DCF fair value for The Cigna Group (CI); the reason is set out below. What its filings and market data do show is below. The snapshot also sets out its trading multiples against 5 peers. Snapshot as of Oct 19, 2026.
Model by Miraaj Patel · generated from public market data · Updated Oct 19, 2026 · How these pages are made
Why is there no fair value for CI?
We do not publish a fair value for The Cigna Group. What we can say from its filings and market data is below.
What is CI's TickerWorth Score?
Cheap against our estimate — but a weaker business
Compared with Healthcare companies in US
Its strongest point: looks cheap on the numbers. Its weakest: balance sheet looks stretched.
- Value · 92 of 100
Cheaper than 92% of Healthcare companies in US
- Price vs worth · 100 of 100
- Quality · 36 of 100
More profitable than 36% of Healthcare companies in US
- Financial health · 30 of 100
Financially stronger than 30% of Healthcare companies in US
- Growth · 41 of 100
Growing faster than 41% of Healthcare companies in US
- Momentum · 53 of 100
Outperformed 53% of Healthcare companies in US over the past year
Confidence: Medium confidence · Scored
Get the Undervalued Company of the Week.
- Price
- $296.77
- Market cap
- $78,
419, 968, 000 - 52-week high
- $311.34
- 52-week low
- $239.51
- Currency
- USD
- Exchange
- NYSE
Snapshot of Oct 19, 2026, quote time not published · Prices are delayed.
What we can say
We don't publish a discounted-cash-flow fair value for The Cigna Group (CI) because the free data sources we rely on don't expose the multi-year financials a DCF needs — common for small or thinly-covered listings. Rather than invent numbers, this page shows an honest snapshot of what the public data does support: the current price and size, any relative valuation multiples that exist, a book-value view, and a price-based read. Treat it as a descriptive starting point, not a valuation and not investment advice.
Read the full reasoning
On the numbers we do have, CI trades at a recent price of $296.77, a market capitalisation of about $78,419,968,000, sitting 80% of the way up its 52-week range ($239.51–$311.34), on the NYSE.
The standard alternative to a DCF is relative valuation — comparing CI's trading multiples against a sector benchmark. Here that gives P/E of 12.3× (cheaper than the peer median of 41.9×); Fwd P/E of 8.9× (cheaper than the peer median of 17.5×); P/B of 1.8× (cheaper than the peer median of 7.8×); P/S of 0.3× (cheaper than the peer median of 6.2×); EV/EBITDA of 8.2× (cheaper than the peer median of 18.5×); Dividend yield of 2.1% (richer than the peer median of 2.4%). A cheaper multiple than peers can flag a discount or a market that expects weaker growth; it is a comparison, not a recommendation.
The asset, or book-value, lens is the classic tool for asset-heavy businesses and financials. CI shows a price-to-book (P/B) of 1.84 and book value of $161.62 per share. Price-to-book compares the market price to the accounting net-asset value per share; below 1.0 can mean a discount to net assets or that the market is pricing in trouble — descriptive either way, never a buy signal on its own.
Finally, a price-based read — explicitly not a valuation. CI is in a mixed trend, trading -4.7% from its 52-week high. Over the past year the stock is -1.5%. Moving-average trend and 52-week position describe where the stock has traded; they say nothing about what it is worth.
CI vs peers
Sector benchmark (bellwethers, not direct competitors).
| Multiple | CI | Peer median | Read |
|---|---|---|---|
| P/E | 12.3× | 41.9× | cheaper than |
| Fwd P/E | 8.9× | 17.5× | cheaper than |
| P/B | 1.8× | 7.8× | cheaper than |
| P/S | 0.3× | 6.2× | cheaper than |
| EV/EBITDA | 8.2× | 18.5× | cheaper than |
| Dividend yield | 2.1% | 2.4% | richer than |
What does The Cigna Group do?
What does it do?
The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. It operates through two segments: Evernorth Health Services and Cigna Healthcare. It operates in the Healthcare Plans industry (Healthcare sector), headquartered in United States. The company employs roughly 65,669 people.
How does it make money?
The business turns $274.9B in annual revenue into profit. Out of every $100 of sales, about $4 is left as operating profit (operating margin of 4.0%), after a 9% gross margin on the products/services it sells. After all costs, taxes and interest, 2.3% of revenue becomes bottom-line net profit.
Is it financially healthy?
Financially it looks stretched: carries modest debt (0.7× equity), may struggle to cover its short-term bills (0.8× current ratio), and is currently profitable.
Who at CI filed insider trades?
| Date | Insider | Relationship | What happened | Value | Filing |
|---|---|---|---|---|---|
| Neville Everett | See Remarks | Open-market sale | $175,258.85 | Form 4 for Neville Everett (opens sec.gov in a new tab) | |
| Evanko Brian C | See Remarks | Grant / award | — | Form 4 for Evanko Brian C (opens sec.gov in a new tab) | |
| Jones Nicole S | See Remarks | Open-market sale | $748,515.97 | Form 4 for Jones Nicole S (opens sec.gov in a new tab) | |
| Jones Nicole S | See Remarks | Option exercise | $249,818.02 | Form 4 for Jones Nicole S (opens sec.gov in a new tab) | |
| Jones Nicole S | See Remarks | Option exercise | $2,696,920.90 | Form 4 for Jones Nicole S (opens sec.gov in a new tab) | |
| Jones Nicole S | See Remarks | Open-market sale | $5,369,583.72 | Form 4 for Jones Nicole S (opens sec.gov in a new tab) |
A disclosure, not a signal to trade. Source: SEC EDGAR (Form 4). Older filings and the 90-day buying-and-selling read are part of Pro. See plans
Companies we do put a number on
Not investment advice. TickerWorth Score is a model output.
A descriptive, available-data snapshot and relative comparison — NOT a DCF, NOT a price target, and NOT investment advice. TickerWorth is not a licensed investment adviser, and these figures are estimates from public market data that can be wrong, stale or incomplete.